Medical specialties

Incyte Announces First Presentation of Phase 3 Data from the TRuE-AD Program of Ruxolitinib Cream at the Revolutionizing Atopic Dermatitis Virtual Symposium

Sunday, April 5, 2020 - 1:00pm

Incyte (Nasdaq: INCY) today announced the first presentation of Phase 3 data for ruxolitinib cream in atopic dermatitis at the Revolutionizing Atopic Dermatitis Virtual Symposium.

Key Points: 
  • Incyte (Nasdaq: INCY) today announced the first presentation of Phase 3 data for ruxolitinib cream in atopic dermatitis at the Revolutionizing Atopic Dermatitis Virtual Symposium.
  • Data that will be presented today during the Revolutionizing Atopic Dermatitis Virtual Symposium show that ruxolitinib cream significantly reduced both the skin inflammation and itch associated with atopic dermatitis.
  • The overall safety profile of ruxolitinib cream in atopic dermatitis was consistent with previous study data, with no new safety signals observed.
  • The potential of ruxolitinib cream to become an important treatment option for patients living with atopic dermatitis is exciting.

Performance Physical Therapy Launches Telehealth Platform

Saturday, April 4, 2020 - 11:25pm

In an effort to continue to treat patients experiencing existing or new musculoskeletal pain, Performance Physical Therapy has instituted Telehealth physical therapy services.

Key Points: 
  • In an effort to continue to treat patients experiencing existing or new musculoskeletal pain, Performance Physical Therapy has instituted Telehealth physical therapy services.
  • In response, Performance Physical Therapy immediately launched a virtual Telehealth platform, Performance PT NOW.
  • Michelle Collie, CEO at Performance Physical Therapy states, "The feedback from our community regarding Performance PT NOW has been overwhelmingly positive.
  • Performance Physical Therapy has temporarily moved to a Telehealth practice to minimize exposure and the spread of COVID-19.

Care Oncology's Telemedicine Model Ideal for Cancer Patients Using the COC Protocol Adjunctive Cancer Treatment

Saturday, April 4, 2020 - 2:00pm

LOS ANGELES, April 4, 2020 /PRNewswire/ --Care Oncology, a UK-based company, today reports higher demand for telemedicine from cancer patients now undergoing treatment.

Key Points: 
  • LOS ANGELES, April 4, 2020 /PRNewswire/ --Care Oncology, a UK-based company, today reports higher demand for telemedicine from cancer patients now undergoing treatment.
  • Patients choose Care Oncology for their unique metabolic therapies that augment the standard of care cancer treatments.
  • He suggests that some patients who elect to pause their standard cancer treatments may consider using the COC Protocol to help weaken their cancer.
  • The COC Protocol is an adjunctive cancer treatment that is designed to work with standard-of-care cancer treatment.

Jichi Medical University and CureApp, Inc.: The First Phase 3 Clinical Trials of "Digital Therapeutics" for Hypertension Begin in Japan

Saturday, April 4, 2020 - 3:07am

*2 Ambulatory blood pressure monitoring: Continuous measurement of blood pressure at certain intervals for 24 hours under normal lifestyle conditions.

Key Points: 
  • *2 Ambulatory blood pressure monitoring: Continuous measurement of blood pressure at certain intervals for 24 hours under normal lifestyle conditions.
  • stroke, heart disease), and the annual death toll in Japan from these diseases attributed to hypertension is estimated to reach 100,000.
  • Hypertension Digital Therapeutics: Joint development with Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine.
  • "Digital Therapeutics" is the registered trademark of CureApp, Inc.
    Head Office Location: Kodenma-Cho YS Building 4th floor, 12-5, Nihonbashi Kodenma-Cho, Chuo-ku, Tokyo, Japan

20/20 BioResponse Confirms Accuracy of Rapid Coronavirus Test Kits in Hospitals in Several U.S. States

Friday, April 3, 2020 - 11:55pm

20/20 BioResponse, a business unit of 20/20 GeneSystems, Inc. announced today that it will begin shipping its CoronaCheck COVID-19 Rapid Antibody Test Kit.

Key Points: 
  • 20/20 BioResponse, a business unit of 20/20 GeneSystems, Inc. announced today that it will begin shipping its CoronaCheck COVID-19 Rapid Antibody Test Kit.
  • One of the evaluators, Dr. Charles H. Miranda, MD, from South Denver Internal Medicine, reported the product to be highly reliable.
  • The test kits are rapid immunoassays (configured like a home pregnancy test) to detect IgM and IgG antibodies to SARS-CoV-2 in blood.
  • The subject test, made in China and approved by the Chinese FDA, was previously evaluated in using 188 clinical samples.

Local Nonprofit Receives Federal Grant for CA Newborn Hearing Screening Program

Friday, April 3, 2020 - 10:28pm

Under the new grant, the program will continue to collaborate with the California Departments of Education (CDE), State Schools for the Deaf; Healthcare Services Coordination Centers, Hearing Coordination Centers; Social Services, Deaf Access Program; and Developmental Services, Regional Programs.

Key Points: 
  • Under the new grant, the program will continue to collaborate with the California Departments of Education (CDE), State Schools for the Deaf; Healthcare Services Coordination Centers, Hearing Coordination Centers; Social Services, Deaf Access Program; and Developmental Services, Regional Programs.
  • "The Newborn Hearing Screening Program illustrates the importance of early detection and intervention.
  • "This grant will support their Newborn Hearing Screening Program to address early language acquisition of children who are deaf or hard of hearing.
  • NorCal Services for Deaf & Hard of Hearing is a nonprofit community-based organization serving Deaf & Hard of Hearing individuals in 24 northeastern counties.

XBiotech and BioBridge Global Collaborate on FDA Program to Develop Potential COVID-19 Treatment Based on Natural Antibodies from Recovered Patients

Friday, April 3, 2020 - 9:53pm

The testing technology will allow QualTex to identify blood that contains naturally neutralizing antibodies against the virus in patients who have recovered from COVID-19 (convalescent donors).

Key Points: 
  • The testing technology will allow QualTex to identify blood that contains naturally neutralizing antibodies against the virus in patients who have recovered from COVID-19 (convalescent donors).
  • XBiotech is a fully integrated, global biopharmaceutical company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies.
  • XBiotech currently is advancing a pipeline of therapies based on harnessing naturally occurring antibodies from patients with immunity to certain diseases.
  • XBiotechs True Human antibodies are the only available antibodies derived without modification from humans who possess natural immunity to certain diseases.

AgraFlora’s 2.2 Million Square Foot Delta Greenhouse Moves Toward Licensing

Friday, April 3, 2020 - 10:00pm

On April 3rd 2020, the Delta Facility submitted responses to the third request for more information (the RMI) from Health Canada with respect to its cultivation application.

Key Points: 
  • On April 3rd 2020, the Delta Facility submitted responses to the third request for more information (the RMI) from Health Canada with respect to its cultivation application.
  • The information submitted pursuant to the third RMI was submitted to clarify information previously submitted to Health Canada on February 28, 2020.
  • AgraFlora believes that the Company has taken the last major step towards licensing, having submitted robust responses to Health Canadas requests in February and now again in March.
  • In addition, AgraFloras wholly owned subsidiary Farmako GmbH is scaling towards its goal of being Europes leading distributor of medical cannabis.

Walmart Changes Shopping Process to Encourage Social Distancing

Friday, April 3, 2020 - 9:55pm

We want to encourage customers to bring the fewest number of people per family necessary to shop, allow for space with other customers while shopping, and practice social distancing while waiting in lines.

Key Points: 
  • We want to encourage customers to bring the fewest number of people per family necessary to shop, allow for space with other customers while shopping, and practice social distancing while waiting in lines.
  • Were also seeing states and municipalities set varying policies regarding crowd control which has created some confusion regarding shopping.
  • Associates and signage will remind customers of the importance of social distancing while theyre waiting to enter a store especially before it opens in the morning.
  • Well continue to put signage inside our stores to remind customers of the need to maintain social distancing especially in lines.

No Borders, Inc. (Ticker:NBDR) Has Begun Receiving and Shipping of the 15 Minute COVID-19 Serological Tests in the USA

Friday, April 3, 2020 - 8:55pm

Through our medical supply chains, the Company has been able to import a 15 minute COVID-19 test for distribution.

Key Points: 
  • Through our medical supply chains, the Company has been able to import a 15 minute COVID-19 test for distribution.
  • While the manufacturers of these tests have applied for their respective EUAs, the FDA has not approved of these tests as of yet.
  • These tests that MediDent Supplies is shipping into the USA use whats called a serological technique, which looks for antibodies in a patients blood.
  • No Borders, Inc. disclaims any obligation to update any of its forward-looking statements, except as may be required by law.